CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aprea Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aprea Therapeutics Inc
3805 OLD EASTON ROAD
Phone: (617) 463-9385p:617 463-9385 DOYLESTOWN, PA  18902  United States Ticker: APREAPRE

Business Summary
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board RichardPeters 60 8/23/2023 6/30/2020
President, Chief Executive Officer, Director OrenGilad 55 7/28/2022 5/1/2022
Chief Financial Officer, Senior Vice President, Secretary John P.Hamill 59 1/30/2023 1/30/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Atrin Pharmaceuticals Inc. 3805 Old Easton Rd Doylestown PA United States

Business Names
Business Name
APRE
Aprea Therapeutics AB
Aprea US, Inc.
ATR Pharmaceuticals LLC
ATRIN PHARMACEUTICALS LLC

General Information
Number of Employees: 7 (As of 12/31/2023)
Outstanding Shares: 5,430,215 (As of 3/26/2024)
Shareholders: 215
Stock Exchange: NASD
Federal Tax Id: 842246769
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024